One of the potential drugs “Remdesivir” for Coronavirus had failed in the first randomised clinical trials.
The world is in the hope that Remdesivir drugs may help to treat Coronavirus infected patients. But a accidentally published draft by WHO confirmed that the drugs in the trials. The draft had been revert back by WHO.
“A draft document was provided by the authors to WHO and inadvertently posted on the website and taken down as soon as the mistake was noticed. The manuscript is undergoing peer review and we are waiting for a final version before WHO comments,” said Tarik Jasarevic, a WHO spokesperson.
According to the reports, researchers studied 237 patients out of which 158 person received Remdesivir drugs and the remaining received Placebo.
After a month, 13.9% of the patients taking the drug had died compared to 12.8% of those receiving the placebo. The trial was stopped early because of side-effects.
This drugs is made by a US company called Gilead Sciences.
“We believe the post (WHO draft) included inappropriate characterisations of the study,” a spokesman for Gilead said, adding that it was terminated early due to low enrolment and was therefore not statistically meaningful.
“As such, the study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease,” he said.